Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vazkepa: ‘Constructive Discussions' Help Amarin Win Reimbursement For ‘Hundreds Of Thousands’ In UK

Reimbursement Discussions Progressing In Other European Markets

Executive Summary

Amarin’s drug, which costs £144.21 for a 30-day supply, is to be made available on the National Health Service in England and Wales for reducing the risk of cardiovascular events after NICE reversed its previous rejection of the product.

You may also be interested in...

Finance Watch: Resilience Raises $625m, Bringing New Cash To $1.2bn

The biomanufacturing firm National Resilience has raised more than $2bn in venture capital and millions more in fees from government and industry contracts since 2020. Also, Code Biotherapeutics raised $75m in series A cash, Concert grossed $66.4m and Amarin is cutting US jobs. 

Sweden Says Yes To Vazkepa Reimbursement But England Says No For Now

Amarin’s treatment is to be made available in Sweden for cardiovascular risk reduction at a price of SEK1,640 per month. But England’s health technology assessment body has concerns over the drug’s cost effectiveness.

Hikma Is Prepared For Tougher Pricing Environment In 2022

Hikma is prepared for additional competitors on key products as well as growing price pressure in the US, CEO Siggi Olafsson tells Generics Bulletin in the second part of an exclusive interview.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts